Dedicated to making hemophilia treatment available to every patient—worldwide.
Through a uniquely imaginative combination of patented, high efficiency biology and portable production to make long-acting factors, Cell Machines can efficiently address the cost and complexity of hemophilia treatment.
Because of a clear regulatory path, Cell Machines’ hemophilia products may be market ready in just a few years—allowing previously untreated patients access to life-changing therapies that were out of their reach—until now.
HEMOPHILIA: A global disease largely treated only in the developed world.
75% of patients in developing economies receive no treatment because it is unavailable or unaffordable.
And in most developed countries, the use of highly recommended prophylactic treatment is lower than 50% due to the high cost of preventive infusions.
American payers report between 82-95% of costs of covering hemophilia are factor-driven. Cell Machines can drop that cost and increase prophylaxis use.